Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-09583 MBIA INC. (Exact name of registrant as specified in its charter) Connecticut (State or other jurisdiction of incorp ...

Exhibit 99.1 Clearwater Analytics Announces Second Quarter 2025 Financial Results Quarterly Revenue of $181.9 Million, Up 70% Year-Over-Year Annualized Recurring Revenue of $783.5 Million, Up 83% Year-Over-Year Adjusted EBITDA of $58.3 Million, Up 74% Year-Over-Year BOISE, Idaho, CHICAGO, NEW YORK, LONDON and HONG KONG — August 6, 2025 — Clearwater Analytics Holdings, Inc. (NYSE: CWAN) ("Clearwater Analytics" or the "Company"), the most comprehensive technology platform for investment management, today anno ...

WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-39165 BLUE RIDGE BANKSHARES, INC. (Exact name of registrant as specified in its charter) Virginia 54-183 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Washington, D.C. 20549 For the transition period from to FORM 10-Q Commission File No. 001-37852 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 PROTAGONIST THERAPEUTICS, INC. For the quarterly period ended June 30, 2025 (Exact name of registrant as specified in its charter) Delaware 98-0505495 (State or oth ...

ANNUITIES & LIFE F&G Investor Update Summer 2025 Disclaimer & Forward-Looking Statements This presentation contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are beyond our control. Some of the forward-looking statements can be identified by the use of terms such as "believes". "expects", "may", "will", "could", "seeks", "intends", "plans", "estimates", "anticipates" or other comparable terms. Statements that. are not historical facts, including ...

Exhibit 99.1 • Revenue of $173.3 million, up 6% year-over-year • Contribution ex-TAC of $162.0 million, up 10% year-over-year, exceeded guidance of $154 to $160 million (1) • Contribution ex-TAC attributable to CTV of $71.5 million, up 14% year-over-year (15% excluding political), at the high end of the guidance range of $70 to $72 million (1) • Contribution ex-TAC attributable to DV+ of $90.4 million, up 8% year-over-year, exceeded guidance of $84 to $88 million, marking twenty consecutive quarters of grow ...

Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress Strong royalties portfolio performance with $67.3 million in revenue IST achieved U.S. net product sales of $29.0 million, reflecting 54% year-over-year growth ZEVTERA (ceftobiprole medocaril sodium, for injection) launched in the U.S. Zoliflodacin NDA accepted by FDA with Priority Review; PDUFA date set for December 15, 2025 BURLINGAME, Calif. – August 6, 2025 – Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Compa ...

Adjusted net earnings attributable to common shareholders (adjusted net earnings) for the second quarter were $318 million, or $1.16 per share, compared to $338 million, or $1.24 per share, for the second quarter of 2024. Company Highlights William P. Foley, II, Chairman, commented, "Our business continued to perform well through the second quarter highlighted by an industry leading pre-tax Title margin and strong adjusted net earnings from our Title segment, as the housing market continues to face elevated ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number 1-9210 _____________________ OCCIDENTAL PETROLEUM CORPORATION (Exact name of registrant as specified in its charter) Del ...

EXHIBIT 99.2 Global Net Lease, Inc. Supplemental Information Quarter ended June 30, 2025 (unaudited) Global Net Lease, Inc. Supplemental Information Quarter ended June 30, 2025 (Unaudited) Table of Contents | Item | Page | | --- | --- | | Non-GAAP Definitions | 4 | | Key Metrics | 6 | | Consolidated Balance Sheets | 7 | | Consolidated Statements of Operations | 8 | | Non-GAAP Measures | 9 | | Debt Overview | 11 | | Future Minimum Lease Rents | 12 | | Top Twenty Tenants | 13 | | Diversification by Property T ...